Sesen Bio’s Richard Fitzgerald to Depart, Monica Forbes Is Named CFO

Richard Fitzgerald, chief financial officer of Sesen Bio (NASDAQ: [[ticker:SESN]]) for the past 19 months, will leave the company on Aug. 30, the company announced Monday. Cambridge, MA-based Sesen gave no reason for Fitzgerald’s departure. Monica Forbes, the company’s vice president of finance, was promoted to CFO effective immediately. Sesen, formerly known as Eleven Biotherapeutics, has advanced lead program Vicinium to Phase 3 testing in bladder cancer. The experimental treatment is being prepared for a submission for FDA review in the fourth quarter of this year.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan